Biohaven Ltd. (BHVN) Stock Price & How to Invest

Last updated November 2026

Short answer

BHVN (Biohaven Ltd) is a clinical-stage biopharma that spun out of Biohaven Pharmaceutical after Pfizer bought its CGRP migraine franchise, so investing in it means underwriting a deep, pre-major-revenue neuroscience, immunology and obesity pipeline whose value hinges on trial readouts, partnering deals and cash runway rather than current sales. As of November 20, 2026 the stock closed near $12.85, up about 19% year to date and about 34% over one year.

BHVN stock price

As of 2026-11-20, Biohaven Ltd. (BHVN) last closed at $12.39, up 27.9% over the past year. Over the past 52 weeks it has traded between $8.09 and $16.95.

BHVN last close
$12.39
1 day
-9.23%
1 month
+5.45%
1 year
+27.86%
52-week range
$8.09 to $16.95
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Biohaven Ltd.'s investor relations page. Walnut is informational, not investment advice.

BHVN key stats

At $12.39 on November 20, 2026, Biohaven Ltd. (BHVN) has a market cap of $1.9B.

Market cap
$1.9B
Beta
3.13

Market cap, P/E and yield are measured at the $12.39 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Biohaven Ltd. (BHVN)?

The last two weeks for Biohaven Ltd., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • BHVN closed at $12.39 on November 20, 2026, down 10.3% over the past five trading days (from $13.82).
  • On November 16, 2026, Biohaven Ltd. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 19, 2026, JP Morgan raised its target to $35.00 from $14.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Biohaven Ltd. (BHVN) do?

Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies across neuroscience, immunology, obesity and oncology. It was created in 2022 when Pfizer acquired the original Biohaven's CGRP migraine business (including Nurtec ODT) for roughly $11.6 billion; the remaining non-CGRP pipeline was spun out into the current publicly traded Biohaven Ltd. Its programs include taldefgrobep alfa (a myostatin-activin pathway inhibitor being tested in obesity and spinal muscular atrophy), troriluzole (VYGLXIA, targeted at spinocerebellar ataxia), opakalim (BHV-7000, a Kv7 ion channel activator for focal epilepsy and depression), MoDE and TRAP extracellular degraders such as BHV-1300 (now in Phase 3 for Graves' disease) and BHV-1400 (IgA nephropathy), and antibody-drug conjugates such as BHV-1530.

The investment picture is that of a high-risk, catalyst-driven biotech. Biohaven has had no product revenue and funds a large research budget through equity raises and, increasingly, licensing deals, so it burns cash and posts sizable net losses (about $543 million over the twelve months to September 2026). The FDA issued a Complete Response Letter for troriluzole in spinocerebellar ataxia in November 2025, which shifted attention to the obesity, epilepsy and degrader programs; Biohaven has since resubmitted, and the FDA accepted the filing with a goal date in the first quarter of 2027 and a planned advisory committee meeting. Since mid-2026 the news flow has been mixed: an August agreement with SK Biopharmaceuticals for the Kv7 platform worth $400 million ($350 million at closing, $50 million a year later) that was still awaiting closing conditions at the end of October, an FDA partial clinical hold on new enrollment in opakalim epilepsy trials over a metabolite seen in rodent studies, and an October 2026 licensing deal with Ono Pharmaceutical worth up to $100 million in near-term payments for its IgG degraders in Japan and parts of Asia. The third-quarter report on October 29 showed a net loss of about $129 million ($0.86 per share), narrower than a year earlier, and cash of about $164 million, and it moved the taldefgrobep obesity readout to the second half of 2027. The stock tends to move on trial news and financing rather than fundamentals, and it closed near $12.85 on November 20, 2026, up about 19% year to date and about 34% over one year, though down about 11% over three months.

What's driving Biohaven Ltd. (BHVN)?

1. Taldefgrobep obesity readout, now in 2027

Biohaven's Phase 2 proof-of-concept study of taldefgrobep alfa in obesity had been guided to read out in the second half of 2026. In its third-quarter report the company said it is amending the study to add a GLP-1 combination arm, and topline data from the monotherapy and combination portions are now expected in the second half of 2027. The differentiated pitch is muscle-sparing weight loss versus GLP-1 drugs, where a large share of lost weight can be lean muscle, and testing it alongside a GLP-1 matches how such a drug would most likely be used. A positive readout would open a new, large addressable market for the company, but investors now wait a year longer for it.

2. Opakalim epilepsy and depression, now with a regulatory delay

Opakalim (BHV-7000), a Kv7 potassium channel activator, is in Phase 3 testing for adult focal epilepsy and is also being studied in major depressive disorder. On September 4, 2026 the FDA placed a partial clinical hold on new enrollment while Biohaven answers questions about a metabolite that appeared in rodent studies; patients already randomized continue dosing. Biohaven says RISE 3 topline data remain on track for the second half of 2026, while RISE 2 enrollment is paused pending nonclinical data. The Kv7 platform is also the subject of the pending $400 million SK Biopharmaceuticals deal. Success here would still give Biohaven a potential lead commercial neuroscience asset, but the timeline is less certain than it was earlier in 2026.

3. Extracellular degrader platform and partnering

Biohaven's MoDE and TRAP degrader technology targets removal of disease-driving proteins and antibodies. Lead program BHV-1300 is enrolling a registrational Phase 3 trial in Graves' disease at more than 50 US and Canadian sites, and BHV-1420, a TRAP degrader for membranous nephropathy, was the subject of an oral presentation at ASN Kidney Week in October 2026, and in October 2026 Biohaven licensed its pan-IgG degraders (BHV-1300, BHV-1310 and BHV-1320) to Ono Pharmaceutical for Japan, South Korea, Taiwan and ASEAN countries: $80 million upfront (received October 20), a $20 million milestone expected within about a year, and royalties of about 20% on Ono's sales there. Biohaven keeps the US, Europe and China. The platform gives the company multiple shots on goal and a source of non-dilutive capital.

4. Breadth as a hedge

Unlike single-asset biotechs, Biohaven carries a broad pipeline spanning obesity, epilepsy, ataxia, SMA, immunology, and oncology, where its FGFR3-directed ADC BHV-1530 showed confirmed responses in FGFR3-altered urothelial and head and neck cancers in early Phase 1 data presented at the EORTC-NCI-AACR symposium in November 2026. Troriluzole, the ataxia drug the FDA turned down in 2025, is back under review with a first-quarter 2027 goal date. This diversification means no single failure is necessarily fatal to the company, though it also spreads capital across many expensive trials at once.

What are the risks to Biohaven Ltd. (BHVN)?

Biohaven has no product sales and posts large quarterly net losses (about $129 million in Q3 2026, against an analyst consensus that had expected licensing income to produce a small profit), so it depends on equity financing and licensing deals; equity raises dilute existing shareholders. Cash stood at about $164 million at the end of September 2026 against about $264 million of notes payable, before the $80 million Ono upfront received in October and before the SK Biopharmaceuticals deal, whose $350 million closing payment still depends on remaining conditions. The 2025 Complete Response Letter for troriluzole and the 2026 partial clinical hold on opakalim show regulatory outcomes can go against the company, and the troriluzole decision in early 2027 and several late-stage readouts are binary events that could sharply move the stock in either direction. The obesity field is intensely competitive and dominated by well-capitalized GLP-1 players, taldefgrobep's muscle-sparing thesis is still unproven in humans at scale, and its readout has slipped to 2027. Cash runway relative to a heavy research budget is a persistent concern that investors should monitor.

What is the Biohaven Ltd. (BHVN) forecast?

15 analysts publish price targets on BHVN, averaging $25.13 as of November 2026, or +102.8% against the $12.39 share price on November 20, 2026. The published targets run from $9.00 to $48.00, a wide spread, and the ratings split 12 buy, 4 hold, 1 sell. Over the last six months there have been 6 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full BHVN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is BHVN a buy or a sell?

We give no verdict on Biohaven Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Taldefgrobep obesity readout, now in 2027. Biohaven's Phase 2 proof-of-concept study of taldefgrobep alfa in obesity had been guided to read out in the second half of 2026. The most optimistic published target, $48.00, assumes this works close to its best case.

The case against. Biohaven has no product sales and posts large quarterly net losses (about $129 million in Q3 2026, against an analyst consensus that had expected licensing income to produce a small profit), so it depends on equity financing and licensing deals; equity raises dilute existing shareholders. The most pessimistic target, $9.00, is roughly what BHVN is worth if this bites instead.

Read the full bull and bear case on BHVN, including what would have to change to break either one. Walnut is not an investment adviser.

Has Biohaven Ltd. (BHVN) split its stock?

No. Biohaven Ltd. (BHVN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Biohaven Ltd. (BHVN) valued?

Market cap, P/E and dividend yield at today's price are in the BHVN key stats above. The business figures below come from Biohaven Ltd.'s reported results as of November 2026 and change when it next reports.

  • 52-week range: ~$8.03 to ~$18.24
  • Q3 2026 net loss: ~$129M (EPS -$0.86 vs ~+$0.16 est.)
  • Net loss (TTM): ~$543M
  • Cash / notes payable (Q3 2026): ~$164M / ~$264M
  • Ono licensing deal (Oct 2026): $80M upfront received, up to $100M near term
  • SK Biopharmaceuticals deal (pending): $400M ($350M at closing)

As of November 2026: Biohaven trades as a pipeline-value biotech rather than on earnings, with a market cap near $1.9 billion and no product revenue. The quarterly loss has narrowed from about $173 million in Q3 2025 to about $129 million in Q3 2026 as research spending fell, but the licensing income analysts had pencilled into the third quarter did not appear because the Ono payment arrived after quarter end. Consensus now looks for fourth-quarter revenue of about $147 million and EPS of about $0.44 as deal payments are recognized. Cash of about $164 million at the end of September keeps financing and runway front of mind, which is why closing the SK Biopharmaceuticals deal matters.

Who competes with Biohaven Ltd. (BHVN)?

Obesity and metabolic drug developers

Companies pursuing next-generation weight-loss therapies, including Eli Lilly, Novo Nordisk, and Amgen, plus muscle-preservation-focused players like Scholar Rock and Veru. Taldefgrobep alfa competes for a muscle-sparing niche within this fast-moving GLP-1-dominated field.

Neuroscience-focused biotech

Developers of epilepsy, depression, and rare neurological disease therapies such as Sage Therapeutics, Praxis Precision Medicines, and Xenon Pharmaceuticals. Biohaven's opakalim and troriluzole programs compete for clinical differentiation and eventual prescriber attention in CNS indications; Xenon's September 2026 trial setback in its own Kv7 program was read by some commentators as a possible opening for opakalim.

Immunology and protein-degrader platforms

Companies advancing targeted protein or antibody degradation and autoimmune therapies, including Arvinas, Kymera Therapeutics, and larger immunology franchises. Biohaven's MoDE and TRAP degraders (BHV-1300, BHV-1400) enter a crowded and well-funded field of novel-modality developers.

What stocks are similar to Biohaven Ltd. (BHVN)?

Other names that sit close to BHVN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Biohaven Ltd. (BHVN)

There are three common ways to get BHVN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so BHVN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where BHVN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Biohaven Ltd. (BHVN)

Biohaven is a real operating drug developer with a broad pipeline and a binary, catalyst-driven profile, so its story is about upcoming clinical and regulatory events (an FDA decision on troriluzole due in the first quarter of 2027, opakalim epilepsy data guided for the second half of 2026, and a taldefgrobep obesity readout now pushed to the second half of 2027) and about non-dilutive licensing cash, not present-day earnings.

More on Biohaven Ltd. (BHVN)

Whether BHVN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BHVN a buy or a sell?, and where the stock could go from here in the BHVN stock forecast.

For income investors, whether BHVN pays a dividend and how the payout looks is covered in does BHVN pay a dividend? And to weigh BHVN against a peer, read the full side-by-side comparisons: BHVN vs LLY and BHVN vs NVO.

Wondering how BHVN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Biohaven Ltd.

Ask Walnut's AI anything about BHVN and see how it fits what you own.

FAQ

What does Biohaven (BHVN) do?

+

Biohaven is a clinical-stage biopharmaceutical company developing drugs across neuroscience, immunology, obesity and oncology. Its pipeline includes taldefgrobep alfa for obesity and SMA, opakalim for epilepsy, troriluzole for spinocerebellar ataxia, extracellular degrader programs for immune diseases such as BHV-1300 in Graves' disease, and antibody-drug conjugates.

Is BHVN the same as the old Biohaven that Pfizer bought?

+

Not exactly. Pfizer acquired the original Biohaven's CGRP migraine business, including Nurtec ODT, in 2022 for about $11.6 billion. The remaining non-CGRP pipeline was spun out into the current publicly traded company, Biohaven Ltd, which trades under BHVN.

Does Biohaven make money?

+

No, Biohaven has no product revenue and posts large net losses: about $129 million in Q3 2026 and about $543 million over the twelve months to September 2026. It funds operations through equity raises and licensing deals rather than product sales. Analysts expect licensing payments from Ono and SK Biopharmaceuticals to make Q4 2026 profitable (consensus EPS about $0.44), a one-off rather than a recurring profit, and still expect a full-year 2026 loss of about $1.39 per share.

What are Biohaven's most important upcoming catalysts?

+

The nearest are RISE 3 topline data for opakalim in focal epilepsy, which Biohaven still guides for the second half of 2026, and the FDA decision on the troriluzole resubmission, with a goal date in the first quarter of 2027 and an advisory committee meeting planned. Closing the $400 million SK Biopharmaceuticals deal is another near-term event. BHV-1300 is enrolling a Phase 3 trial in Graves' disease, and the taldefgrobep obesity readout has moved to the second half of 2027.

What happened with troriluzole?

+

The FDA issued a Complete Response Letter for Biohaven's troriluzole (VYGLXIA) application in spinocerebellar ataxia on November 4, 2025, meaning it declined to approve the drug as submitted. The setback prompted cost cutting and shifted investor focus toward the obesity, epilepsy and degrader programs. Biohaven later resubmitted, and its October 2026 report said the FDA accepted the resubmission with a goal date in the first quarter of 2027 and plans an advisory committee meeting; RBC wrote in October that approval could transform the company.

How is taldefgrobep different from GLP-1 weight-loss drugs?

+

Taldefgrobep alfa is a myostatin-activin pathway inhibitor designed to reduce fat while preserving or building muscle. GLP-1 drugs can drive a large share of weight loss from lean muscle, so Biohaven positions taldefgrobep as a muscle-sparing option, potentially usable alone or alongside GLP-1s. This muscle-sparing benefit is still being tested.

Why is BHVN considered a high-risk stock?

+

Its value depends on binary clinical and regulatory outcomes rather than current earnings, and a single failure or FDA action can move the stock sharply, as the 2026 opakalim partial clinical hold showed. It also burns cash (about $164 million on hand at the end of September 2026) and relies on dilutive equity financing and partnering, so runway and trial results are the dominant risk factors.

How large is Biohaven and what is its cash position?

+

As of November 20, 2026 Biohaven had a market cap of roughly $1.9 billion with a share price near $12.85. It reported cash, equivalents, marketable securities and restricted cash of about $164 million and notes payable of about $264 million at the end of September 2026. It received the $80 million Ono upfront on October 20, and the SK Biopharmaceuticals deal would add $350 million at closing and $50 million a year later.

What is the Biohaven and Ono Pharmaceutical deal?

+

Announced October 8, 2026, the deal gives Ono an exclusive license to develop and sell Biohaven's pan-IgG degraders (BHV-1300, BHV-1310 and BHV-1320) in Japan, South Korea, Taiwan and ASEAN countries. Biohaven receives $80 million upfront, a $20 million milestone it expects within about a year, and royalties of about 20% on Ono's net sales in that territory, while keeping rights in the US, Europe and China.

How has BHVN stock performed in 2026?

+

As of the November 20, 2026 close near $12.85, BHVN was up about 19% year to date and about 34% over one year, though down about 11% over three months and below its 52-week high near $18.24. The shares slid in late summer after the FDA's opakalim enrollment hold and a wider-than-expected Q2 loss, then recovered part of the ground in October and November. The 15 analysts tracked by Yahoo Finance rate it a buy on average with a mean target near $25; Deutsche Bank cut its target to $23 from $26 after the third-quarter report. Walnut is not an investment adviser.

How did Biohaven do in its latest quarter?

+

For Q3 2026 (reported October 29), Biohaven posted a net loss of about $129.3 million, or $0.86 per share, against $173.4 million a year earlier, as research spending fell to about $101.9 million from $141.2 million. Analysts had expected a small profit of about $0.16 per share on licensing income, but the Ono upfront was received after quarter end. The company also moved the taldefgrobep obesity readout to the second half of 2027 and confirmed the troriluzole goal date in the first quarter of 2027.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Biohaven Ltd.'s investor relations page or your broker before making investment decisions.